Urate-lowering therapy for gout: Difficulties in goal achieving the and ways to overcome

Author:

Krasivina I. G.1ORCID,Dolgova L. N.2ORCID,Dolgov N. V.2ORCID

Affiliation:

1. Yaroslavl State Medical University

2. Yaroslavl State Medical University; Clinical Hospital “RZD-Medicine” in the city of Yaroslavl

Abstract

Introduction. The effectiveness of gout treatment is assured by achieving a serum uric acid target level, which is currently accepted by most national clinical guidelines and consensus as < 360 µmol/L. Achievement of therapy goals is ensured by modification of patients’ lifestyle and adequate prescription of urate-reducing therapy and often involves a number of difficultiesAim. To analyze the frequency of prescription and success of urate-reducing therapy in patients with gout over a five-year observation period in real clinical practice.Materials and methods. Retrospective evaluation of the management of 104 patients (72 men and 32 women) with gout diagnosed for the first time in 2018, followed up to and including 2023. We analyzed the adequacy of urate-reducing therapy prescription, frequency of arthritis exacerbations, and presence of comorbidities in subgroups achieving or not achieving uric acid target level < 360 µmol/L.Results. 26 people achieved uric acid target level, with a comparable ratio of men and female in subgroups of achieving or not achieving. The fact of achieving uric acid target level was recorded during the first year of observation and was maintained subsequently. Prescription of urate-reducing therapy was registered in 42% of the group, but in only 41% of them it was adequate. Even with adequate prescription of allopurinol, 1/3 of the patients did not achieve uric acid target level. The prescription of an alternative uricostatic agent, febuxostat, was noted in only 9% of patients.Conclusions. Achieving total control in gout in real clinical practice noted in 25%, and urate-reducing therapy was prescribed in 42% of patients. Urate-lowering therapy was prescribed adequate in less than 1/2 of patients. Alternative uricostatic to allopurinol febuxostat was prescribed in less than 1/10 of patients. Opportunity achievement of the urate-reducing therapy goal was determined within the first year from diagnosis gout. If the uric acid target level is not reached within a given period of time, it is necessary analyze the reasons for failure and prescribe or intensify urate-reducing therapy.

Publisher

Remedium, Ltd.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3